Abstract: The present invention relates to a process for preparing a compound of formula (V) where R is H or F, by reacting a compound of formula (IV) where R is H or F, with hydrogen sulphide or salts thereof, optionally in the presence of a reaction auxiliary and optionally in the presence of a diluent.

Abstract: The invention relates to the field of blood coagulation, more particularly, to novel compounds of general formula (I), to a method for producing said compounds and to their use as active ingredients in medicaments for the prevention and/or the treatment of diseases.

Abstract: The present invention relates to a process for preparing compounds of the formula (I) where R is H or F, by (a) reacting a compound of the formula (II) where X is halogen, mesylate or tosylate with a thiocyanate, (b) reacting the resultant product with H2S or one of its salts to give a dithiocarbamate, and (c) reacting the dithiocarbamate with acetaldehyde, chloroacetaldehyde or an acetal thereof, and further relates to intermediates used in this process.

Abstract: This invention relates to compounds of formula (I) wherein R1 represents optionally substituted phenyl, R2 represents optionally substituted and the remaining “R” groups are as defined in the specification and claims, as well as a method for making such materials, pharmaceutical compositions containing such materials, and methods of using such materials in medical treatment.

Abstract: The present invention relates to a process for preparing heterocyclic fluoroalkenyl sulfones and fluoroalkenyl sulfoxides by allowing the corresponding fluoroalkenyl thioethers to react with a salt of peroxomonosulfuric acid (H2SO5), optionally in the presence of a reaction assistant and optionally in the presence of a diluent.

Abstract: This invention relates to methods for treating thromboembolic disorders and ischemias, sexual dysfunction, inflammation, disorders of the central nervous system, and cardiovascular disorders other than hypertension by administering a compound of the formula wherein R1 is H or a di-C1-6-alkylaminocarbonyl radical, and R2 is a radical of the formula —O—C(X)—NR3R4 wherein X is O or S. The compound may also be administered in combination with at least one organic nitrate or NO donor, or in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

Abstract: This invention relates to methods of treatment of cardiovascular disorders, thromboembolic disorders, inflammation, and disorders of the central nervous system using pyrazol pyridine derivatives of formula (I) wherein R1 is a radical of the formula —O—SO2-R3 in which R3 is optionally substituted C1-6-alkyl, optionally substituted C3-8-cycloalkyl, or optionally substituted phenyl; R2 is H, optionally substituted C1-6-alkyl-CO— or optionally substituted C1-6-alkyl-SO2—; as well as salts, stereoisomers, tautomers, and hydrates thereof.

Abstract: The invention relates to the field of blood clotting, to novel compounds of formula (I), to a method for their production and to the use of these compounds as active ingredients in medicaments for preventing and/or treating diseases. The compounds are factor Xa inhibitors.

Abstract: This invention relates to pyrazol pyridine derivatives of formula (I) wherein R1 is a radical of the formula ?O—SO2—R3 in which R3 is optionally substituted C1—6—alkyl, optionally substituted C3—8—cycloalkyl, or optionally substituted phenyl; R2 is H, optionally substituted C1—6—alkyl —CO—or optionally substituted C1—6—alkyl—SO2— ; as well as salts, stereoisomers, tautomers, and hydrates thereof. Pharmaceutical compositions containing these materials and methods of using them in medical treatment are also described and claimed.

Abstract: The present invention relates to a process for preparing compounds of the formula (I) where R is H or F, by (a) reacting a compound of the formula (II) where X is halogen, mesylate or tosylate with a thiocyanate, (b) reacting the resultant product with H2S or one of its salts to give a dithiocarbamate, and (c) reacting the dithiocarbamate with acetaldehyde, chloroacetaldehyde or an acetal thereof, and further relates to intermediates used in this process.

Abstract: The invention relates to novel pyrazolopyridine derivatives of formula (I) wherein R1 represents NH2 or NHCO-C1-6-alkyl, and R2 represents a radical of formula R3NCOR4 which is bonded to the remainder of the molecule by means of the nitrogen atom, R3 and R4 forming, together with the amide group to which they are bonded, a five to seven-membered heterocycle which may be saturated or partially unsaturated, may optionally contain a further heteroatom selected from the group N, O, and S and may comprise between one and five other substituents chosen from oxo, C1-6alkyl, hydroxyl, hydroxy-C1-6-alkyl, halogen, or may be fused to a C6-10 ARYL ring or a C3-8 cycloalkyl ring in which optionally two carbon atoms are bonded to each other by means of an oxygen atom.

Abstract: The invention relates to the field of blood coagulation, more particularly, to novel compounds of general formula (I), to a method for producing said compounds and to their use as active ingredients in medicaments for the prevention and/or the treatment of diseases.

Abstract: The invention relates to the field of blood clotting, to novel compounds of formula (I), to a method for their production and to the use of these compounds as active ingredients in medicaments for preventing and/or treating diseases. The compounds are factor Xa inhibitors.

Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.

Abstract: The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.

Abstract: The invention relates to novel pyrazolopyridine derivatives of formula (I), wherein R1 represents (a) or (b) and n represents 1 or 2 and R2 represents H NH2. The invention also relates to salts, isomers and hydrates thereof as stimulators for soluble guanylate cyclase and to their use as agents in the treatment of cardiovascular diseases, hypertonicity, thrombo-embolic diseases and ischemia, sexual dysfunction or inflammations and for the treatment of diseases of the central nervous system.

Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) 1

Abstract: The invention relates to coagulation of the blood.

Abstract: The invention relates to novel pyrazol pyridine derivatives of formula (I), wherein R1 signifies a radical of formula —O—SO2—R3, R3 represents a radical from the group consisting of optionally substituted C1-6-alkyl, optionally substituted C3-8-cycloalkyl, or optionally substituted phenyl, R2 represents H or optionally substituted C1-6-alkyl-SO2—; in addition to the salts, isomers and hydrates thereof, as stimulators of soluble guanylate cyclase, and to the use thereof as agents for treating cardio-vascular diseases, hypertonia, thromboembolic diseases and ischaemia, sexual dysfunction or inflammations and for treating diseases of the central nervous system 1

Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which R1, R2, R3 and A are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.